GlassScriptPhysician profile
Miriam D Warren
NPI 1659875458
$4,936.87
in general payments reported to CMS, 2019-2025
42 companies · $2,005 in 2025
The $2,005 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $665 · 2023: $676 · 2024: $1,458 · 2025: $2,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,139.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,428.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $589.80 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $482.82 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $261.00 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $183.61 | 2023-2025 | Austedo Xr, Austedo Xr |
| Daiichi Sankyo INC. | $165.49 | 2021-2022 | |
| Boston Scientific Corporation | $148.47 | 2023-2024 | |
| Janssen Biotech, INC. | $143.60 | 2025 | Rybrevant |
| Glaxosmithkline, LLC. | $134.98 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $114.68 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $102.41 | 2022-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $101.27 | 2021-2025 | Ubrelvy |
| Biohaven Pharmaceutical Holding Company LTD. | $94.68 | 2022 | |
| Merz Pharmaceuticals, LLC | $86.04 | 2024-2025 | Xeomin, Inbrija |
| Neurocrine Biosciences, INC. | $84.14 | 2023-2024 | Ingrezza |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.